Collegium Pharmaceutical Inc. has announced that it will present four poster presentations highlighting real-world data on its ADHD product, Jornay PM (methylphenidate HCl), at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference, scheduled for January 15-18, 2026, in San Diego, California. The poster session is set to take place on January 17, 2026. The presentations will cover topics including determining the optimal dose of Jornay PM in adolescents and adults with ADHD, evaluation of risks and benefits compared to Concerta, changes in morning and evening functioning in children and adolescents, and changes in depression and anxiety severity in adults treated with Jornay PM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9625936-en) on January 15, 2026, and is solely responsible for the information contained therein.